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Background:  Stentless  prostheses  have  an  interesting  hemodynamic  performance  when  compared  to
stented  prostheses  and  are  recommended  in  cases  of  small  aortic  annulus.
Materials  and methods:  From  January  1996  to  January  2004,  138  patients  suffering  from  aortic  disease,
underwent  aortic  valve  replacement.
• Group  A: 93  patients  underwent  stentless  aortic  valve  implantation  [stentless  Biocor (Biocor  Industria
e  Pesguisa  Ltda,  Belo  Horizonte,  Brazil)  and  stentless  Sorin  (Sorin  Group,  Saluggia,  Italy)].
• Group  B:  45  patients  underwent  stented  aortic  valve  implantation  (stented  Biocor).  Patients  were
assessed  by  clinical  evaluation  and  echocardiography  after  a mean  follow  up  of 124.5 ± 58.2  months.
Results:  There  was  a  signiﬁcant  difference  in  terms  of  time  of  extracorporeal  circulation  and  aortic  cross
clamp. The  actuarial  survival  at 4, 8, 12, and  15  years  is 77%,  50%,  21%,  and  18%,  respectively.  Freedom
from  reoperation  at 4,  8, 12,  and  14 years  was  92%,  83%,  73%,  and  63%, respectively.  Freedom  from  all
events,  death,  and  reoperation  at 4, 8, 12, and  14 years  was  70%,  39%,  13%, and  8%, respectively.  There  is
no  statistical  difference  among  the  two  groups  in terms  of  actuarial  survival,  freedom  from  reoperation,
and  freedom  from  re-hospitalization  for prosthesis-related  causes.
Discussion:  There  was a signiﬁcantly  higher  incidence  of  pacemaker  implantation  in Group  A and  the
causes  are  not  known.  The  rate  of freedom  from  reoperation  is high  in  both  groups  for  the  patients  who
remained  alive.  There  was  no statistical  difference  about  prosthesis  dysfunction  between  the  two  groups.
The higher  incidence  of  death  in Group  A  cannot  be  explained  by causes  related  to the  prosthesis  because
there  is  no difference  in terms  of causes  of  death.  Rates  of reoperation  did  not  differ  between  the  two
groups.
Conclusions:  The  results  obtained  with  stentless  prostheses  are  encouraging  even  in  long-term  follow-up.
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Aortic valve replacement (AVR) is a safe procedure with sig-
iﬁcant improvements in survival for patients affected by aortic
alve disease. Stentless prostheses are widely accepted as a safe
ption mainly for the elderly affected by aortic stenosis with heavy
alciﬁed annulus [1].
Although porcine aortic valves or pericardial tissue mounted
n a stent made the implantation technique easier, these valves
acriﬁced oriﬁce area and increased stress at the attachment of the
tent, which caused earlier primary tissue failure [2].
∗ Corresponding author. Tel.: +39 115082812; fax: +39 115082860.
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Reports of the operative mortality of stentless and stented AVR
have differed in the literature. Retrospective and prospective ran-
domized controlled studies showed similar operative mortality and
morbidity. Although stentless AVR required longer cross-clamp and
cardiopulmonary bypass time, it did not impair the postopera-
tive outcomes. In patients with depressed left ventricular function,
operative outcomes were better in stentless valves owing to the
larger effective oriﬁce area (EOA) when the full-root technique was
applied to avoid patient–prosthetic mismatch [3].
We present the long-term follow-up of patients who underwent
AVR with different models of stentless prosthesis.Materials and methods
Institutional Review Board and Ethics Committee approval
was obtained before we performed research analysis using the
vier Ltd. All rights reserved.
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Table 1
Preoperative details of Groups A and B.
Characteristic Group A
(93 patients: 67.4%)
Group B
(45 patients: 32.6%)
Age (years) 60.5 ± 12.4 64.7 ± 10.4
COPD 5 (5.4%) 6 (13.3%)
Redo surgery 29 (31.2%) 6 (13.3%)
Vascular disease 3 (3.2%) 3 (6.6%)
Previous CVE 3(3.2%) 1 (2.2%)
Obesity 8 (8.6%) 3 (6.6%)
Smoke 19 (20.4%) 9 (19.8%)
Systemic hypertension 41 (44.1%) 18 (40.0%)
Diabetes 8 (8.6%) 4 (8.9%)
Dyslipidemia 11 (11.8%) 11 (24.4%)
Chronic renal failure 5 (5.4%) 0
Atrial ﬁbrillation 8 (8.6%) 5 (11.1%)
NYHA class 2.5 ± 0.5 2.5 ± 0.666 F. Sansone et al. / Journal o
nstitution’s database. All the patients signed the informed con-
ent, having been explained the beneﬁts and disadvantages of this
urgical approach.
reoperative details of the whole population
From January 1996 to January 2004, 138 patients (89 males;
ean age 62.0 ± 11.9 years) suffering from aortic stenosis (57
atients – 41%), regurgitation (23 patients – 17%), or combined
isease (26 patients – 19%), underwent isolated AVR.
Twenty-seven patients (20%) underwent emergency operations
ue to an acute pulmonary edema or cardiac failure.
Thirty-two patients (23%) had previously undergone opera-
ions (29 patients ﬁrst redo surgery, 3 patients second redo
urgery). Causes of reoperation were: para-valvular regurgitation
9 patients) and prosthetic dysfunction (23 patients).
Fourteen patients (10.1%) had a bicuspid aortic valve.
The New York Heart Association (NYHA) class was: 74 patients
54%) class II, 60 (43%) class III, and 4 (3%) class IV. Twelve patients
8.7%) had preoperative atrial ﬁbrillation.
All the patients were operated through full sternotomy and the
ardiopulmonary bypass was established amongst the ascending
orta and the right atrium. The cold blood cardioplegia (31 ◦C) was
dministered to the aortic root and to the coronary ostia subse-
uently.
The aortic valve was approached by a transverse aortotomy.
Three different biological prostheses were implanted:
52 (37%) stentless Biocor – Biocor Industria e Pesguisa Ltda, Belo
Horizonte, Brazil – (6 prosthesis size 21, 7 prosthesis size 23, 19
prosthesis size 25, 10 prosthesis size 27, 10 prosthesis size 29);
41 (30%) stentless Sorin – Sorin Group, Saluggia, Italy – (6 pros-
thesis size 21, 13 prosthesis size 23, 7 prosthesis size 25, 10
prosthesis size 27, 5 prosthesis size 29);
45 (33%) stented Biocor – Biocor – (4 prosthesis size 21, 19
prosthesis size 23, 16 prosthesis size 25, 4 prosthesis size 27, 2
prosthesis size 29).
The stentless Biocor prosthesis and the Sorin stentless pros-
hesis were sutured by three continuous sutures of polypropylene
/0 whilst the stented prosthesis was ﬁxed by three ethibond 3/0
titches on the commissures and three polypropylene sutures on
he aortic annulus. Mean duration of cardiopulmonary bypass (CPB)
as 95.0 ± 22.0 min  (range 57–229 min) and the mean aortic cross
lamp was 75.0 ± 12.0 min  (range 42–157 min).
etails of the study groups
The study population was divided into two different groups
Table 1):
Group A: 93 patients (24 females; mean age 60.5 ± 12.4 years)
underwent stentless aortic valve implantation (stentless Biocor
and stentless Sorin). Twenty-nine patients (31.2%) underwent
redo surgery and 20 patients (21.5%) had urgent surgery for car-
diac failure or pulmonary edema. Mean value of ejection fraction
was 33.6 ± 17.2% and the aortic root diameter was 36.5 ± 6.8 mm.
A total of 13 patients (14%) had a bicuspid aortic valve and 25
(26.9%) had acute endocarditis. A total of 48 patients (51.6%) had
predominant aortic stenosis and 16 patients (17.2%) had aortic
regurgitation. Among patients with aortic stenosis, peak gradi-
ent across the valve was 73.6 ± 35.0 mmHg  and mean gradient
was 42.3 ± 19.6 mmHg  with an EOA of 0.8 ± 0.5 cm2. Mean dura-
tion of extracorporeal circulation was 100.0 ± 25.1 min  and aortic
cross clamp was 80.5 ± 18.7 min.COPD, chronic obstructive pulmonary disease; CVE, cerebro-vascular event; NYHA,
New York Heart Association.
• Group B: 45 patients (22 females; mean age 64.7 ± 10.4 years)
underwent stented aortic valve implantation (stented Biocor).
Six (13.3%) patients underwent redo surgery and 7 patients
(15.5%) had urgent surgery for cardiac failure or pulmonary
edema. Mean value of ejection fraction was 44.6 ± 14.2% and
the aortic root diameter was  32.8 ± 4.9 mm.  One patient (2.2%)
had a bicuspid aortic valve and 8 (17.8%) had acute endo-
carditis. A total of 33 patients (73.3%) had predominant aortic
stenosis and 6 patients (13.3%) had aortic regurgitation. Among
patients with aortic stenosis, peak gradient across the valve
was  79.3 ± 29.7 mmHg  and mean gradient was 47.7 ± 21.3 mmHg
with an EOA of 0.9 ± 0.6 cm2. Mean duration of extracorpo-
real circulation was 83.3 ± 20.4 min  and aortic cross clamp was
64.0 ± 16.3 min.
The preoperative details of Groups A and B are summarized in
Table 1.
Statistical analysis
Continuous variables are expressed as mean ± standard devia-
tion and categorical variables as a percentage. All the patients still
alive (after a follow up to 15 years) were assessed by echocardiogra-
phy comparing preoperative and postoperative data by univariate
analysis using the 2 test.
Actuarial survival, freedom from reoperation, and freedom
from major acute cardiac events were expressed according to the
Kaplan–Meier curves.
Results
From the surgical point of view, there was a signiﬁcant dif-
ference in terms of time of extracorporeal circulation for the
stentless and stented implantation respectively (100.0 ± 25.1 min
vs 83.3 ± 20.4 min; p < 0.05); this difference is conﬁrmed even for
the aortic cross clamp for the stentless and stented implanta-
tion, respectively (80.5 ± 18.7 min  vs 64.0 ± 16.3 min; p < 0.05). The
detailed results of each group are summarized below and in Table 2.
Short-term follow-up
Group A
Eight patients required re-exploration for bleeding; 2 patientshad mediastinitis requiring surgery and two other patients had
deep wound infections which did not require surgery (Table 2). Four
patients had acute renal failure and 1 of them required dialysis; 5
patients had pulmonary complications (1 acute pulmonary failure
F. Sansone et al. / Journal of Card
Table  2
Postoperative complications.
Postoperative
complications
Group A
(93 patients: 67.4%)
Group B
(45 patients: 32.6%)
p
Re-exploration for
bleeding
8 4 NS
Fever 1 2 NS
Atrial ﬁbrillation 10 8 NS
Pacemaker implantation 20 1 <0.05
Ventricular ﬁbrillation 1 0 NS
Left  or right bundle block 5 0 NS
Reoperation for
perivalvular leakage
1 0 NS
Sternal dehiscence
requiring surgery
2 0 NS
Wound infection
(medications)
2 0 NS
Acute myocardial
infarction
1 0 NS
Renal failure 4 1 NS
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were evaluated by echocardiography. Ejection fraction increased
from 42.8 ± 12.4% to 61.2 ± 8.4% (p < 0.05), the peak gradient across
the valve decreased from 85.5 ± 31.2 mmHg  to 26.3 ± 13.3 mmHgPulmonary failure 5 1 NS
Early deaths 6 2 NS
equiring prolonged mechanical ventilation, 1 pneumonia; 1 pneu-
othorax and 2 pleural effusion requiring percutaneous drainage).
en had atrial ﬁbrillation requiring intravenous amiodarone and 20
atients required pacemaker implantation for complete atrioven-
ricular block; 1 patient required surgery for paravalvular leak and 1
atient had fever. The perioperative mortality was 6.4% (6 patients).
roup B
Four patients required re-exploration for bleeding; no patient
ad mediastinitis or deep wound infections (Table 2). One patient
ad acute renal failure which did not require dialysis; 1 patient had
ulmonary complications (1 pleural effusion requiring percuta-
eous drainage). Eight had atrial ﬁbrillation requiring intravenous
miodarone and 1 patient required pacemaker implantation for
omplete atrio-ventricular block; no patient required surgery for
aravalvular leak and 2 patients had fever. The perioperative mor-
ality was 4.4% (2 patients).
ong-term follow-up
All the alive patients who did not require prosthesis replace-
ent (32 patients, 23.2%; 15 in Group A and 17 in Group B) at
ollow-up (124.5 ± 58.2 months) were assessed by clinical evalu-
tion and echocardiography. The follow-up was complete at 100%
nd closed in May  2010. Of the 138 patients, 51 (37.0%) were alive,
7 (63.0%) had died, and 21 (15.2%) were re-operated.
The actuarial survival for the whole population at 4, 8, 12, and 15
ears is 77%, 50%, 21%, and 18%, respectively (Fig. 1A). The actuarial
urvival for each group is shown in Fig. 1B and the difference did
ot reach statistical signiﬁcance (log rank p = 0.285).
Freedom from reoperation for the whole population at 4, 8, 12,
nd 14 years was 92%, 83%, 73%, and 63%, respectively (Fig. 2A).
reedom from reoperation for each group is shown in Fig. 2B and the
ifference did not reach statistical signiﬁcance (log rank p = 0.130).
Freedom from all events, death, and reoperation for the whole
opulation at 4, 8, 12, and 14 years was 70%, 39%, 13%, and
%, respectively (Fig. 3A). Freedom from re-hospitalization for
rosthesis-related causes for each group is shown in Fig. 3B and
here is not a signiﬁcant difference among the two  groups (log rank
 = 0.779).
All the living patients who did not require prosthesis replace-ent (32 patients, 15 males, mean age 73.0 ± 12.0 years, range
7–90 years), underwent echocardiography (Table 3) after a
ean follow up of 11.3 ± 1.6 years revealing a statistically sig-
iﬁcant increase in the ejection fraction from 40.0 ± 16.2% toiology 63 (2014) 365–372 367
58.0 ± 10.2% (p < 0.05), reduction of the left ventricular end
diastolic diameters from 35.7 ± 11.7 mm to 31.9 ± 7.9 mm
(p < 0.05), and a reduction in the gradients across the valve (peak
gradient from 84.2 ± 38.8 mmHg  to 23.6 ± 12.7 mmHg (p < 0.05)
and mean gradient from 48.1 ± 22.8 mmHg to 12.4 ± 7.0 mmHg
(p < 0.05)).
Group A
A total of 28 patients (32.2%) of the 87 patients that were dis-
charged after the operation (6 early deaths) were alive as of May
2010 (Table 4) and 13/28 of them underwent re-operation: 2 for
acute endocarditis and 11 for prosthesis dysfunction after a mean
period of 73.2 ± 47.4 months (16.8–146.4 months). A total of 59
patients died during the follow-up and causes of death were as
follows:
• Prosthesis-related in 23 patients (2 patients died during reope-
ration) after a mean follow-up of 95.3 ± 43.2 months.
• Cardiac-related for congestive heart failure with normal function-
ing prosthesis in 11 patients after a mean follow-up of 63.4 ± 35.9
months.
• Not cardiac-related in 25 patients (usually for malignancies or
cerebro-vascular events) after a mean follow-up of 83.8 ± 42.2
months.
Fifteen patients (53.6% of the survivors, 16.2% of the Group
A) who  did not undergo redo surgery for prosthesis dysfunc-
tion after a mean follow-up of 145.2 ± 19.9 months (110.3–172.8
months) were evaluated by echocardiography. Ejection frac-
tion increased from 30.8 ± 13.7% to 49.9 ± 17.3% (p < 0.05), the
peak gradient across the valve decreased from 82.2 ± 50.8 mmHg
to 28.5 ± 19.1 mmHg  (p < 0.05), and the mean gradient from
40.8 ± 20.7 mmHg to 15.3 ± 10.6 mmHg  (p < 0.05). All patients were
in good clinical condition with a signiﬁcant reduction of the NYHA
class and with no discomfort related to the prosthesis.
Group B
A total of 23 patients (53.5%) of the 43 patients that were dis-
charged after the operation (2 early death) were alive as of May
2010 (Table 4) and 6/23 of them underwent re-operation: 1 for
endocarditis and 5 for prosthesis dysfunction after a mean period
of 40.7 ± 16.9 months (26.4–72.9 months). Twenty patients died
and causes of death were as follows:
• Prosthesis-related in 8 patients due to prosthesis dysfunction
after a mean follow-up of 57.1 ± 41.6 months.
• Cardiac-related for congestive heart failure with normal function-
ing prosthesis in 3 patients after a mean follow-up of 87.4 ± 21.7
months.
• Not cardiac-related in 9 patients (usually for malignancies or
cerebro-vascular events) after a mean follow-up of 87.7 ± 36.9
months.
Seventeen patients (73.9% of the survivors, 37.8% of the Group
B) who  did not undergo redo surgery for prosthesis dysfunction
after a mean follow-up of 127.2 ± 11.9 months (108–152.4 months)(p < 0.05), and the mean gradient from 53.2 ± 23.5 mmHg to
14.4 ± 7.5 mmHg  (p < 0.05). All patients were in good clinical con-
dition with a signiﬁcant reduction in the NYHA class and with no
discomfort related to the prosthesis.
368 F. Sansone et al. / Journal of Cardiology 63 (2014) 365–372
Fig. 1. (A) Actuarial survival of the whole population. (B) Actuarial survival of the Groups A and B. There is no signiﬁcant difference between Groups A and B.
F. Sansone et al. / Journal of Cardiology 63 (2014) 365–372 369
Fig. 2. (A) Freedom from reoperation of the whole population. (B) Freedom from reoperation of the Groups A and B. There is no signiﬁcant difference between Groups A
and  B.
370 F. Sansone et al. / Journal of Cardiology 63 (2014) 365–372
Fig. 3. (A) Freedom from major events for the whole population. (B) Freedom from re-hospitalization for prosthesis-related causes of the Groups A and B.
F. Sansone et al. / Journal of Cardiology 63 (2014) 365–372 371
Table  3
Data from echocardiography (11.3 ± 1.6 years) of the whole population.
Pre-operative echocardiography (mean ± SD) Postoperative echocardiography (mean ± SD) p
EF (%) 40.0 ± 16.2 58.0 ± 10.2 <0.05
TSD  vs (mm) 35.7 ± 11.7 31.9 ± 7.9 <0.05
TDD  vs (mm) 54.5 ± 10.1 52.1 ± 7.5 <0.05
LA  (mm)  42.5 ± 6.3 42.1 ± 5.9 n.s.
AA  diameter (mm) 33.8 ± 5.1 35.3 ± 7.1 n.s
Peak  grad (mmHg) 84.2 ± 38.8 23.6 ± 12.7 <0.001
S , left 
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D, standard deviation; TSD, tele-systolic diameter; TDD, tele-diastolic diameter; LA
iscussion
AVR is nowadays a safe procedure with low rates of mortal-
ty and morbidity and the progressive increase of the number of
rocedures goes hand in hand with the improvement in the rhe-
logy of the prosthesis and the reduction of the invasiveness of
he surgical approach [4,5]. However, the mean age of patients
ontinues to increase and the heavily calciﬁed aortic annulus may
uggest a stentless prosthesis implantation, ensuring a larger EOA
reventing peri-valvular leakage [2]. However, when implanting a
tentless prosthesis, care must be taken to exclude the presence
f any aortic annular discontinuity, avoiding late complications
s pseudo-aneurysm [6]. New strategies, such as the trans-apical
r percutaneous approaches, allow a further increase in numbers
f eligible patients even though they are restricted to high-risk
atients, as long as there are no surgical contraindications. On the
ontrary, the stentless prosthesis has many advantages compared
ith stented valves and they are recommended in the case of small
ortic annuli or serious calciﬁcation mainly in the elderly [2–7]. Pre-
ious studies provided evidence that stentless and stented valves
ave similar hemodynamic proﬁles in the small aortic root when
atched on true measured internal diameters. The clinical beneﬁt
f the stentless porcine valve may  be due to patient selection or the
ack of a rigid stent in the small aortic root [8–10].
We have recently reported our initial experience using the stent-
ess prosthesis through a right thoracotomy, achieving appreciable
esults in terms of morbidity and mortality in the short term [1].
ince there is a long experience in our division with the stentless
rosthesis that started to be used in the early 1990s and because
here is lack of data concerning the long-term follow-up of these
rostheses, we analyzed the results achieved at our institution after
 long follow-up of 11.3 ± 1.6 years.
The operative mortality in our series (8 patients, 5.8%) is quite
igh compared to recent papers describing the minimally invasive
pproaches [1,4,11] and it may  depend on the different techniques
sed more than 20 years ago. The innovations over the years led
o a signiﬁcant reduction in mortality and morbidity of patients
perated on for AVR. Moreover, an important number of patients
23%) had already been previously operated (29 patients ﬁrst redo
urgery, 3 patients second redo surgery), mainly in Group A and
able 4
ummary of the long-term follow-up details.
Long-term follow-up Group A
(N: 93)
Group B
(N: 45)
p
Living patients 28 23 <0.05
Reoperations among living patients 13 6 NS
Prosthesis dysfunction 34 13 NS
Overall deaths 66 22 <0.05
Prosthesis-related deaths 23 8 NS
Cardiac-related deaths 11 3 NS
No  cardiac-related deaths 25 9 NS
Ejection fraction (%) 49.9 ± 17.3% 61.2 ± 8.4% <0.05
Peak gradient (mmHg) 28.5 ± 19.1 26.3 ± 13.3 NS
Mean gradient (mmHg) 15.3 ± 10.6 14.4 ± 7.5 NS12.4 ± 7.0 <0.001
atrium; AA, ascending aorta; grad, gradient.
this may  affect the results in terms of mortality that was 6.4% in
Group A vs 4.4% in Group B. Thus, the background characteristics of
the two  groups are different because the mean age of Group A was
younger than that of Group B, but Group A had signiﬁcantly lower
preoperative LV function and higher rate of redo surgery. Thus, the
two groups were not similar and the high-risk patients were more
frequent in Group A than in Group B. However, the aim of this paper
is to report the experience over the long-term follow-up with these
prostheses and every attempt of scientiﬁc comparison of the two
groups would reduce too much the population. In fact, the aim of
this paper is to describe this long experience with these prostheses.
In terms of surgical procedure, our experience conﬁrms that the
surgical implantation of the stentless prosthesis is longer compared
to that of stented prosthesis with a signiﬁcant difference in terms
of CPB and aortic cross clamp time. However, this difference may
be reduced by the increase of the surgical skill during implantation.
Of note is the high incidence of pacemaker implantation for
complete atrioventricular block that is the major complication in
this series. Previous studies suggested that the requirement for
a pacemaker resulted from either operative trauma or increased
ischemic burden and the incidence of pacemaker implantation was
independent of prosthesis-type implanted [12]. Regardless of the
discussion about the role of the decalciﬁcation of the aortic annulus
that may  cause damage to the atrioventricular ﬁbers, other factors
may  induce this complication: in our series there is a signiﬁcantly
higher incidence of pacemaker implantation in Group A, where the
decalciﬁcation is usually less aggressive and causes are not avail-
able at the moment. However, we  can speculate that several risk
factors such as low left ventricular ejection fraction, long bypass
time, and prosthetic valve size may  play a role. In fact, in Group
A where the incidence of complete atrioventricular block requir-
ing pacemaker implantation is more frequent, the ejection fraction
is low, the bypass time is longer, and the size of the prosthesis is
usually bigger (20 prostheses 27 mm and 15 prostheses 29 mm in
Group A vs 4 prostheses 27 mm and 2 prostheses 29 mm in Group
B).
Extremely interesting is the rate of freedom from reoperation
(80% at 10 years) as well as the rate of survival that is compati-
ble with the mean age of the study population. The Kaplan–Meier
curves for actuarial survival, freedom from reoperation, and free-
dom from re-hospitalization do not show signiﬁcant difference
among the two groups (Figs. 1A, B, 2A, B and 3A, B) and this result
is interesting considering the long follow-up of this population.
From the echocardiographic point of view, there was a signif-
icant improvement in the ejection fraction (from 40.0 ± 16.2% to
58.0 ± 10.2%), of the end-diastolic diameter (from 54.5 ± 10.1 mm
to 52.1 ± 7.5 mm)  and of the left ventricular end-systolic diameter
(from 35.7 ± 11.7 mm to 31.9 ± 7.9 mm)  (Table 3).
Moreover, the diameters of the ascending aorta did not increase
over the years probably due to the absence of turbulence of the ﬂow
across the valve.
However, a more accurate evaluation of the prosthesis may
be obtained by the innovative three-dimensional echocardiogra-
phy that offers more details about the function or damage of the
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rosthesis [13]. Recently, the role of computed tomography scan-
ing has been advocated in the diagnosis of para-valvular leakages
14] that may  be difﬁcult to evaluate by echocardiography.
The results obtained with these stentless prostheses are encour-
ging mostly for the long follow-up considered. In fact, the actuarial
urvival and the freedom from reoperation were similar between
he two groups. Moreover, freedom from re-hospitalization for
rosthesis-related causes is comparable for patients with stentless
nd stented prostheses and this is an important fact considering
he long-term follow-up of this population.
Moreover, freedom from reoperation and prosthesis dysfunc-
ion of the stentless prostheses are at least comparable to those
f biological or mechanical prostheses. In fact, Weber et al. have
ecently reported the survival rate for biological and mechanical
rostheses that are 90.3% and 98% (p = 0.038), respectively after a
ean follow-up of 33 ± 24 months. Freedom from all valve-related
omplications is 54.5% for biological and 51.6% for mechanical
alves (p = NS), whereas freedom from reoperation is 100% for
iological prostheses and 98% for mechanical valves (p = NS). The
esults of this study appear to be better compared to our results
ut there is a signiﬁcant difference in terms of follow-up (33 ± 24
onths vs 11.3 ± 1.6 years of our experience) [15]. In fact, 11/28
atients of Group A and 5/23 patients of Group B had prosthesis dys-
unction requiring redo surgery after a mean period of 73.2 ± 47.4
onths and 40.7 ± 16.9 months, that is signiﬁcantly longer than the
ollow-up considered in the paper by Weber.
All the living patients had relief from effort dyspnea with a
eduction in the NYHA class. Probably, it should be related to the
emoval of the aortic stenosis that led to a decrease of the sys-
olic pulmonary artery pressure that dropped from 49.3 ± 12.5%
reoperatively to 38.1 ± 21.5% postoperatively (p = NS). However,
he experience of medical treatment with phosphodiesterase 5
nhibitors for pulmonary arterial hypertension in cardiac transplant
ecipients [16–18] could be used even in case of pulmonary hyper-
ension in patients operated for valvular heart disease when the
ulmonary arterial hypertension is conﬁrmed to be reversible.
We think that the most important evidence of this paper is that:
There is not a statistical difference in terms of actuarial survival
between the two groups as shown by Kaplan–Meier curves in
Fig. 1B.
There is not a statistical difference in terms of freedom from
reoperation between the two groups as shown by Kaplan–Meier
curves in Fig. 2B.
There is not a statistical difference in terms of freedom from
major events and re-hospitalization for prosthesis-related causes
between the two groups as shown by Kaplan–Meier curves in
Fig. 3B.
From the echocardiographic point of view, there is a signiﬁcant
ifference in terms of increase in the ejection fraction between the
wo groups. Conversely, there is no signiﬁcant difference among
he peak and mean gradient between the two groups.
onclusions
This study concerns the long-term follow up of patients [9] oper-
ted on in our center for AVR with stentless prostheses.
The most interesting results of this retrospective analysis are:
Stentless prostheses are at least comparable to stented prosthe-
ses in terms of actuarial survival and freedom from reoperation.
Stentless prostheses are at least comparable to stented prosthe-
ses in terms of freedom from major events and re-hospitalization
for prosthesis-related causes.
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• The reason for the signiﬁcantly higher incidence of pacemaker
implantation in Group A is unknown even though some risk fac-
tors such as low left ventricular ejection fraction, long bypass
time, and bigger prosthetic valve size in Group A may play a role.
• There was a high rate of freedom from reoperation in both
groups for the living patients. Even for patients who required
redo surgery, it happened after about 73.2 ± 47.4 and 40.7 ± 16.9
months, respectively, in Groups A and B.
• There was no statistical difference concerning prosthesis dys-
function between the two  groups.
• Even though there was  a higher incidence of death in the stentless
group, this cannot be explained by causes related to the prosthesis
because there is no difference in terms of causes of death.
• Rates of reoperation did not differ between the two  groups.
Further experience is required to conﬁrm our results.
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